These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8969330)

  • 21. Roundtable discussion. Cost justification of innovative drugs through assessment of total health care costs.
    Rybak MJ; Allen R; Craven PC; Freeman R; Nightingale CH; Normand C; Rubinstein E; Schaison GS; Whitelaw G
    Hosp Formul; 1993 Jan; 28 Suppl 1():33-6. PubMed ID: 10123836
    [No Abstract]   [Full Text] [Related]  

  • 22. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspectives and prospects for health system reform.
    Mayer JE; Dove JT
    Semin Thorac Cardiovasc Surg; 2009; 21(1):3-6. PubMed ID: 19632556
    [No Abstract]   [Full Text] [Related]  

  • 24. Industry comment on the 1995 revised Australian pharmacoeconomic guidelines.
    Grobler MP; Macarounas-Kirchmann K; Pearce GA; Stafford M
    Pharmacoeconomics; 1996 Apr; 9(4):353-6. PubMed ID: 10160109
    [No Abstract]   [Full Text] [Related]  

  • 25. A cost-effectiveness approach to drug subsidy and pricing in Australia.
    Birkett DJ; Mitchell AS; McManus P
    Health Aff (Millwood); 2001; 20(3):104-14. PubMed ID: 11585158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology.
    van der Greef J; McBurney RN
    Nat Rev Drug Discov; 2005 Dec; 4(12):961-7. PubMed ID: 16341061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?
    Drummond M
    Pharmacoeconomics; 1992; 1(Suppl 1):61-9. PubMed ID: 10146934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. States combat drug costs.
    Consum Rep; 2002 Dec; 67(12):8-9. PubMed ID: 12448442
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmaceuticals in Australia: developments in regulation and governance.
    Lofgren H; Boer Rd
    Soc Sci Med; 2004 Jun; 58(12):2397-407. PubMed ID: 15081192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health care lobbying: time to make patients the special interest.
    Kushel M; Bindman AB
    Am J Med; 2004 Apr; 116(7):496-7. PubMed ID: 15047042
    [No Abstract]   [Full Text] [Related]  

  • 33. Plasmodium: drug discovery and development--an industrial perspective.
    Ridley RG
    Exp Parasitol; 1997 Nov; 87(3):293-304. PubMed ID: 9371097
    [No Abstract]   [Full Text] [Related]  

  • 34. Are we ready for patient-based effect sizes in clinical-trials research?
    Lehmann HP
    Med Decis Making; 2005; 25(3):248-9. PubMed ID: 15951452
    [No Abstract]   [Full Text] [Related]  

  • 35. A place in the sun.
    Abbott A
    Nature; 2007 Mar; 446(7132):124-5. PubMed ID: 17344823
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost containment in the Australian Health Care System--an unexpected success.
    Deeble JS; Smith LR
    Cah Sociol Demogr Med; 2000; 40(1):95-112. PubMed ID: 10965433
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug costs can be defended.
    Lee AM
    Med Mark Media; 1982 Mar; 17(3):36, 38, 40 passim. PubMed ID: 10309584
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug and health outcomes measurement in clinical practice.
    Ibern P
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():45-6. PubMed ID: 9800730
    [No Abstract]   [Full Text] [Related]  

  • 39. An optimistic view from the corporate perspective.
    Baase C
    Am J Health Promot; 2001; 15(5):363-5. PubMed ID: 11502021
    [No Abstract]   [Full Text] [Related]  

  • 40. Study critiques corporate control of trials.
    Niiler E
    Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.